Giant Biogene Holding Co., Ltd. (HKG:2367)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
58.60
-0.60 (-1.01%)
Jul 25, 2025, 10:44 AM HKT
-1.01%
Market Cap62.67B
Revenue (ttm)5.89B
Net Income (ttm)2.19B
Shares Out1.06B
EPS (ttm)2.19
PE Ratio27.00
Forward PE22.39
Dividend1.31 (2.24%)
Ex-Dividend DateJun 17, 2025
Volume2,026,379
Average Volume14,333,815
Open59.05
Previous Close59.20
Day's Range58.05 - 59.20
52-Week Range35.00 - 87.10
Beta0.65
RSI50.79
Earnings DateAug 19, 2025

About Giant Biogene Holding

Giant Biogene Holding Co., Ltd., an investment holding company, designs, develops, manufactures, and sells skin treatment products with recombinant collagen in the People’s Republic of China. It also develops and manufactures rare ginsenosides technology-based functional food products; and offers medical devices. The company provides its functional skincare products, medical dressings, and functional food products primarily under the Comfy, Collgene, Ke Yu, and SKIGIN brands. Giant Biogene Holding Co., Ltd. was founded in 2000 and is headquarte... [Read more]

Founded 2000
Employees 1,758
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2367
Full Company Profile

Financial Performance

In 2024, Giant Biogene Holding's revenue was 5.54 billion, an increase of 57.17% compared to the previous year's 3.52 billion. Earnings were 2.06 billion, an increase of 42.06%.

Financial numbers in CNY Financial Statements

News

Giant Biogene Bruised In A 'Battle Of The Skincare Belles'

A squabble involving false advertising claims by a sinking Bloomage Biotech against highflying rival Giant Biogene has captivated China, with no end in sight Key Takeaways: Shares of Giant Biogene hav...

6 weeks ago - Benzinga